Skin diseases and inflammatory bowel diseases. Literature review
https://doi.org/10.21518/2079-701X-2020-5-114-119
Abstract
The article presents data of some skin diseases, that often appear in inflammatory bowel diseases (IBD).
Some of the skin diseases are directly connected with the activity of the main inflammatory process (erythema nodosum, Crohn’s disease of the skin and mucous, hidradenitis suppurativa) and the main method of the treatment is the decrease of main disease’s activity. Also the patient’s presence of skin lesions shows the presence of body’s system reaction and makes the main disease more difficult to cure. Medications for specific treatment of inflammatory process in the bowel (mesalasine, vedolizumab) for these patients are inefficient, as usual. Besides, patients with hidradenitis suppurativa and pyoderma gangrenous who have difficult cases of skin lesions will need the local therapy in addition to the main treatment. Generally, gastroenterologist needs dermatologist’s help in that case. Some of these diseases are not linked with the activity of inflammatory bowel diseases (“paradoxical” psoriasis, melanoma). The “paradoxical” psoriasis appears in inflammatory bowel diseases patients in the context of medication anti-TNF therapy and can be usually cured with local mecations. In case of inefficient local therapy we can appeal to change the supportive inflammatory bowel diseases therapy with anti-TNF medications to the medications belong to the group of antibodies to IL 12, 23 (ustekinumab). Also, the skin diseases, provoked by the therapy of these diseases (paradoxical psoriasis, melanoma, non-melanomic skin cancer) often appear at patients with inflammatory bowel diseases. The basic in treatment of skin diseases is reduction of activity. However, skin diseases, which are not connected with the inflammatory bowel diseases activity or are complications of therapy require to multidisciplinary approach with necessary participation of dermatologists.
About the Authors
T. L. Alexandrov
A. Ryzhikh State Research Center of Coloproctology
Russian Federation
Russian Federation
Timofey L. Aleksandrov - Junior Researcher, Department of Functional and Inflammatory Bowel Diseases.
2, Salyama Adilya St., Moscow, 123423
I. L. Khalif
A. Ryzhikh State Research Center of Coloproctology
Russian Federation
Russian Federation
Igor L. Khalif - Dr. of Sci. (Med.), Professor, Head of Department for the Study of Inflammatory and Functional Bowel Diseases.
2, Salyama Adilya St., Moscow, 123423, Moscow
A. Yu. Khalif
Bashkir State Medical University
Russian Federation
Russian Federation
Aygul Yu. Khalif - Teaching Assistant, Chair for Dermatovenerology with Dermatovenerology and Cosmetology Modules.
3, Lenina St., Ufa, Republic of Bashkortostan, 450008
Z. R. Khismatullina
Bashkir State Medical University
Russian Federation
Russian Federation
Zarema R. Khismatullina - Dr. of Sci. (Med.), Professor, Chair for Dermatovenerology with Dermatovenerology and Cosmetology Modules.
3, Lenina St., Ufa, Republic of Bashkortostan, 450008
M. V. Shapina
A. Ryzhikh State Research Center of Coloproctology
Russian Federation
Russian Federation
Marina V. Shapina - Cand. of Sci. (Med.), Head of Department of Functional and Inflammatory Bowel Diseases.
2, Salyama Adilya St., Moscow, 123423
References
1. Adaskevich V.P., Myadelec O.D. Eosinophilic and neutrophilic dermatosis. Moscow: Meditsinskaya kniga; 2001. (In Russ.) Available at: https://search.rsl.ru/ru/record/01000710672.
2. Regueiro M., Swoger J. Clinical Challenges and Complications Of IBD. Thorofare; 2013.
3. Tian Y., Li J.X., Wang H.H., Li R.Y, Liu X.G. Clinical analysis of cutaneous manifestations and related factors in patients with ulcerative colitis. Zhonghua Nei Ke Za Zhi. 2016;55(7):505-509. doi: 10.3760/cma.j.issn.0578-1426.2016.07.004.
4. Kim M., Choi K.H., Hwang S.W., Lee Y.B., Park HJ., Bae J.M. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study. J Am Acad Dermatol. 2017;76(1):40-48. doi: 10.1016/j.jaad.2016.08.022.
5. Vavricka S.R., Galvan J.A., Dawson H., Soltermann A., Biedermann L., Scharl M., Schoepfer A.M., Rogler G., Prinz Vavricka M.B., Terracciano L., Navarini A., Zlobec I., Lugli A., Greuter T. Expression Patterns of TNFa, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(3):347-354. doi: 10.1093/ecco-jcc/jjx158.
6. Greuter T., Navarini A., Vavricka S.R. Skin Manifestations of Inflammatory Bowel Disease. Clin Rev Allergy Immunol. 2017;53(3):413-427. doi: 10.1007/s12016-017-8617-4.
7. Fleisher M., Marsal J., Lee S.D., Frado L.E., Parian A., Korelitz B.I., Feagan B.G. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(4):825-833. doi: 10.1007/s10620-018-4971-1.
8. Suh H.Y., Lee WJ., Na S.Y. Dermatologic Manifestations in Inflammatory Bowel Disease. Korean J Gastroenterol. 2019;73(5):285-293. doi: 10.4166/kjg.2019.73.5.285.
9. Dubinsky M.C., Cross R.K., Sandborn WJ., Long M., Song X., Shi N. et al. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(9):1876-1882. doi: 10.1093/IBD/izy065.
10. Masaki S., Bayaraa B., Imafuku S. Prevalence of inflammatory bowel disease in Japanese psoriatic patients. J Dermatol. 2019;46(7):590-594. doi: 10.1111/1346-8138.14900.
11. Jellali K., Mellouki I., Ibrahimi A. Cheilitis granulomatosa revealing Crohn's disease. Pan Afr Med J. 2018;30:147. doi: 10.11604/pamj.2018.30.147.5395.
12. Leung A.K.C., Leong K.F., Lam J.M. Erythema nodosum. World J Pediatr. 2018;14(6):548-554. doi: 10.1007/s12519-018-0191-1.
13. Lukach AJ., Saul M.I., Ferris L.K., Swoger J.M. Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(3):755-760. doi: 10.1007/s10620-018-4919-5.
14. Singh B., Kedia S., Konijeti G., Mouli V.P., Dhingra R., Kurrey L., Srivastava S., Pradhan R., Makharia G., Ahuja V. Extraintestinal manifestations of inflammatory bowel disease and intestinal tuberculosis: Frequency and relation with disease phenotype. Indian J Gastroenterol. 2015;34(1):43-50. doi: 10.1007/s12664-015-0538-7.
15. Yadav S., Singh S., Edakkanambeth Varayil J., Harmsen W.S., Zinsmeister A.R., Tremaine WJ. et aL Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016;14(1):65-70. doi: 10.1016/j.cgh.2015.04.173.
16. Adaskevich V.P., Myadelec O.D. Eosinophilic and neutrophilic dermatosis. Moscow: Meditsinskaya kniga; 2001. (In Russ.) Available at: https://search.rsl.ru/ru/record/01000710672.
17. McNally A., Ibbetson J., Sidhu S. Azathioprine-induced Sweet's syndrome: A case series and review of the literature. Australas J Dermatol. 2017;58(1):53-57. doi: 10.1111/ajd.12383.
18. Tian Y., Li J.X., Wang H.H., Li R.Y, Liu X.G. Clinical analysis of cutaneous manifestations and related factors in patients with ulcerative colitis. Zhonghua Nei Ke Za Zhi. 2016;55(7):505-509. doi: 10.3760/cma.j.issn.0578-1426.2016.07.004.
19. Pietrzak D., Pietrzak A., Krasowska D., Borzęcki A., Franciszkiewicz-Pietrzak K., Polkowska-Pruszyńska B., Baranowska M., Reich K. Digestive system in psoriasis: an update. Arch Dermatol Res. 2017;309(9):679-693. doi: 10.1007/s00403-017-1775-7.
20. Vavricka S.R., Galvan J.A., Dawson H., Soltermann A., Biedermann L., Scharl M., Schoepfer A.M., Rogler G., Prinz Vavricka M.B., Terracciano L., Navarini A., Zlobec I., Lugli A., Greuter T. Expression Patterns of TNFa, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(3):347-354. doi: 10.1093/ecco-jcc/jjx158.
21. LoHi E., Saraceno R., Calabrese E., Ascolani M., Scarozza R, Chiricozzi A. et al. Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study. J Crohns Colitis. 2015;9(9):699-707. doi: 10.1093/ECC0-0KK/jjv068.
22. Fleisher M., Marsal J., Lee S.D., Frado L.E., Parian A., Korelitz B.I., Feagan B.G. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(4):825-833. doi: 10.1007/s10620-018-4971-1.
23. Cottone M., Sapienza C., Macaluso F.S., Cannizzaro M. Psoriasis and Inflammatory Bowel Disease. Dig Dis. 2019;37(6):451-457. doi: 10.1159/000500116.
24. Dubinsky M.C., Cross R.K., Sandborn WJ., Long M., Song X., Shi N. et al. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(9):1876-1882. doi: 10.1093/IBD/izy065.
25. Yablokova E.A., Gorelov A.V., Shevtsova G.V., Polotnyanko E.Yu., Grammatopulo M.I., Borisova E.V, Kanshina A.A. Extraintestinal manifestations of inflammatory bowel diseases in children. Voprosyprakticheskoypediatrii = Clinical Practice in Pediatrics. 2015;3(10):65-74. (In Russ.) Available at: http://www.phdynasty.ru/katalog/zhurnaly/voprosy-prakticheskoy-pediatrii/2015/tom-10-nomer-3/24553.
26. Jellali K., Mellouki I., Ibrahimi A. Cheilitis granulomatosa revealing Crohn's disease. Pan Afr Med J. 2018;30:147. doi: 10.11604/pamj.2018.30.147.5395.
27. Abdulganieva D.I., Bakulev A.L., Belousova E.A., Znamenskaya L.F., Korotaeva T.V, Kruglova L.S. et al. A draft of the interdisciplinary guidelines for diagnosis, methods for assessment of the degree of inflammatory activity, therapeutic efficacy, and for the use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Chrohn's disease). Al’manakh klinicheskoy meditsiny=Almanac of Clinical Medicine. 2018;46(5):426-444. (In Russ.) doi: 10.18786/2072-0505-2018-46-5-426-444.
28. Lukach AJ., Saul M.I., Ferris L.K., Swoger J.M. Risk Factors for Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(3):755-760. doi: 10.1007/s10620-018-4919-5.
29. Hindryckx P., Novak G., Costanzo A., Danese S. Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017;11(3):203-214. doi: 10.1080/17474124.2017.1283985.
30. Pugliese D., Daperno M., Fiorino G., Savarino E., Mosso E., Biancone L. et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Dig Liver Dis. 2019;51(7):972-977. doi: 10.1016/j.dld.2019.03.007.
31. Yadav S., Singh S., Edakkanambeth Varayil J., Harmsen W.S., Zinsmeister A.R., Tremaine WJ. et aL Hidradenitis Suppurativa in Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016;14(1):65-70. doi: 10.1016/j.cgh.2015.04.173.
32. McNally A., Ibbetson J., Sidhu S. Azathioprine-induced Sweet's syndrome: A case series and review of the literature. Australas J Dermatol. 2017;58(1):53-57. doi: 10.1111/ajd.12383.
33. Sanchez-Martinez M.A., Garcia-Planella E., Laiz A., Puig L. Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology. Actas Dermosifiliogr. 2017;108(3):184-191. doi: 10.1016/j.ad.2016.07.007.
34. Pietrzak D., Pietrzak A., Krasowska D., Borzęcki A., Franciszkiewicz-Pietrzak K., Polkowska-Pruszyńska B., Baranowska M., Reich K. Digestive system in psoriasis: an update. Arch Dermatol Res. 2017;309(9):679-693. doi: 10.1007/s00403-017-1775-7.
35. Vedak P, Kroshinsky D., St John J., Xavier RJ., Yajnik V., Ananthakrishnan A.N. Genetic basis of TNF-a antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis. Aliment Pharmacol Ther. 2016;43(6):697-704. doi: 10.1111/apt.13542.
36. LoHi E., Saraceno R., Calabrese E., Ascolani M., Scarozza R, Chiricozzi A. et al. Psoriasis Phenotype in Inflammatory Bowel Disease: A Case-Control Prospective Study. J Crohns Colitis. 2015;9(9):699-707. doi: 10.1093/ECC0-0KK/jjv068.
37. Pugliese D., Guidi L., Ferraro P.M., Marzo M., Felice C., Celleno L. et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015; 42(7):880-888. doi: 10.1111/apt.13352.
38. Cottone M., Sapienza C., Macaluso F.S., Cannizzaro M. Psoriasis and Inflammatory Bowel Disease. Dig Dis. 2019;37(6):451-457. doi: 10.1159/000500116.
39. Melo FJ., Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol. 2018;57(12):1521-1532. doi: 10.1111/ijd.14072.
40. Yablokova E.A., Gorelov A.V., Shevtsova G.V., Polotnyanko E.Yu., Grammatopulo M.I., Borisova E.V, Kanshina A.A. Extraintestinal manifestations of inflammatory bowel diseases in children. Voprosyprakticheskoypediatrii = Clinical Practice in Pediatrics. 2015;3(10):65-74. (In Russ.) Available at: http://www.phdynasty.ru/katalog/zhurnaly/voprosy-prakticheskoy-pediatrii/2015/tom-10-nomer-3/24553.
41. Nidegger A., Mylonas A., Conrad C. Paradoxical psoriasis induced by anti-TNF - a clinical challenge. Rev Med Suisse. 2019;15(644):668-671. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30916904.
42. Abdulganieva D.I., Bakulev A.L., Belousova E.A., Znamenskaya L.F., Korotaeva T.V, Kruglova L.S. et al. A draft of the interdisciplinary guidelines for diagnosis, methods for assessment of the degree of inflammatory activity, therapeutic efficacy, and for the use of biological agents in patients with concomitant immunoinflammatory diseases (psoriasis, psoriatic arthritis, Chrohn's disease). Al’manakh klinicheskoy meditsiny=Almanac of Clinical Medicine. 2018;46(5):426-444. (In Russ.) doi: 10.18786/2072-0505-2018-46-5-426-444.
43. Ezzedine K., Visseaux L., Cadiot G., Brixi H., Bernard P., Reguiai Z., Ustekinumab for skin reactions associated with anti-tumor necrosis factor-а agents in patients with inflammatory bowel diseases: A singlecenter retrospective study. J Dermatol. 2019;46(4):322-327. doi: 10.1111/1346-8138.14816.
44. Hindryckx P., Novak G., Costanzo A., Danese S. Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017;11(3):203-214. doi: 10.1080/17474124.2017.1283985.
45. Afzali A., Wheat C.L., Hu J.K., Olerud J.E., Lee S.D. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8(6):480-488. doi: 10.1016/j.crohns.2013.10.013.
46. Pugliese D., Daperno M., Fiorino G., Savarino E., Mosso E., Biancone L. et al. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. Dig Liver Dis. 2019;51(7):972-977. doi: 10.1016/j.dld.2019.03.007.
47. Bae J.M., Lee H.H., Lee B.I., Lee K.M., Eun S.H., Cho M.L. et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018;48(2):196-205. doi: 10.1111/apt.14822.
48. Sanchez-Martinez M.A., Garcia-Planella E., Laiz A., Puig L. Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology. Actas Dermosifiliogr. 2017;108(3):184-191. doi: 10.1016/j.ad.2016.07.007.
49. Peer F.C., Miller A., Pavli P., Subramaniam K. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients. Intern Med J. 2017;47(12):1445-1448. doi: 10.1111/imj.13637.
50. Vedak P, Kroshinsky D., St John J., Xavier RJ., Yajnik V., Ananthakrishnan A.N. Genetic basis of TNF-a antagonist associated psoriasis in inflammatory bowel diseases: a genotype-phenotype analysis. Aliment Pharmacol Ther. 2016;43(6):697-704. doi: 10.1111/apt.13542.
51. Weizman A.V., Sharma R., Afzal N.M., Xu W., Walsh S., Stempak J.M. et al. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(9):2430-2438. doi: 10.1007/s10620-018-5096-2.
52. Pugliese D., Guidi L., Ferraro P.M., Marzo M., Felice C., Celleno L. et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015; 42(7):880-888. doi: 10.1111/apt.13352.
53. Almutairi D., Sheasgreen C., Weizman A., Alavi A. Generalized Pustular Psoriasis Induced by Infliximab in a Patient with Inflammatory Bowel Disease. J Cutan Med Surg. 2018;22(5):507-510. doi: 10.1177/1203475418758986.
54. Melo FJ., Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol. 2018;57(12):1521-1532. doi: 10.1111/ijd.14072.
55. Eickstaedt J.B., Killpack L., Tung J., Davis D., Hand J.L., Tollefson M.M. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. Pediatr Dermatol. 2017;34(3):253-260. doi: 10.1111/pde.13081.
56. Nidegger A., Mylonas A., Conrad C. Paradoxical psoriasis induced by anti-TNF - a clinical challenge. Rev Med Suisse. 2019;15(644):668-671. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30916904.
57. Udkoff J., Cohen P.R. Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn's Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies. Dermatol Ther (Heidelb). 2016;6(4):689-695. doi: 10.1007/s13555-016-0156-z.
58. Ezzedine K., Visseaux L., Cadiot G., Brixi H., Bernard P., Reguiai Z., Ustekinumab for skin reactions associated with anti-tumor necrosis factor-а agents in patients with inflammatory bowel diseases: A singlecenter retrospective study. J Dermatol. 2019;46(4):322-327. doi: 10.1111/1346-8138.14816.
59. Nissen L.H.C., Pierik M., Derikx L.A.A.P, de Jong E., Kievit W., van den Heuvel T.R.A. et al. Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma. Inflamm Bowel Dis. 2017;23(11):2018-2026. doi: 10.1097/MIB.0000000000001191.
60. Afzali A., Wheat C.L., Hu J.K., Olerud J.E., Lee S.D. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8(6):480-488. doi: 10.1016/j.crohns.2013.10.013.
61. Anderson AJ.M., Ferris L.K., Binion D.G., Smith KJ. Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(10):2564-2572. doi: 10.1007/s10620-018-5141-1.
62. Bae J.M., Lee H.H., Lee B.I., Lee K.M., Eun S.H., Cho M.L. et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018;48(2):196-205. doi: 10.1111/apt.14822.
63. Peer F.C., Miller A., Pavli P., Subramaniam K. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients. Intern Med J. 2017;47(12):1445-1448. doi: 10.1111/imj.13637.
64. Anderson A., Ferris L.K., Click B., Ramos-Rivers C., Koutroubakis I.E., Hashash J.G. et al. Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci. 2018;63(10):2729-2739. doi: 10.1007/s10620-018-5056-x.
65. Weizman A.V., Sharma R., Afzal N.M., Xu W., Walsh S., Stempak J.M. et al. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(9):2430-2438. doi: 10.1007/s10620-018-5096-2.
66. Hagen J.W., Pugliano-Mauro M.A. Nonmelanoma Skin Cancer Risk in Patients with Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature. Dermatol Surg. 2018;44(4):469-480. doi: 10.1097/dss.0000000000001455.
67. Almutairi D., Sheasgreen C., Weizman A., Alavi A. Generalized Pustular Psoriasis Induced by Infliximab in a Patient with Inflammatory Bowel Disease. J Cutan Med Surg. 2018;22(5):507-510. doi: 10.1177/1203475418758986.
68. Eickstaedt J.B., Killpack L., Tung J., Davis D., Hand J.L., Tollefson M.M. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents. Pediatr Dermatol. 2017;34(3):253-260. doi: 10.1111/pde.13081.
69. Udkoff J., Cohen P.R. Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn's Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies. Dermatol Ther (Heidelb). 2016;6(4):689-695. doi: 10.1007/s13555-016-0156-z.
70. Nissen L.H.C., Pierik M., Derikx L.A.A.P, de Jong E., Kievit W., van den Heuvel T.R.A. et al. Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma. Inflamm Bowel Dis. 2017;23(11):2018-2026. doi: 10.1097/MIB.0000000000001191.
71. Anderson AJ.M., Ferris L.K., Binion D.G., Smith KJ. Cost-Effectiveness of Melanoma Screening in Inflammatory Bowel Disease. Dig Dis Sci. 2018;63(10):2564-2572. doi: 10.1007/s10620-018-5141-1.
72. Anderson A., Ferris L.K., Click B., Ramos-Rivers C., Koutroubakis I.E., Hashash J.G. et al. Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci. 2018;63(10):2729-2739. doi: 10.1007/s10620-018-5056-x.
73. Hagen J.W., Pugliano-Mauro M.A. Nonmelanoma Skin Cancer Risk in Patients with Inflammatory Bowel Disease Undergoing Thiopurine Therapy: A Systematic Review of the Literature. Dermatol Surg. 2018;44(4):469-480. doi: 10.1097/dss.0000000000001455.
Review
For citations:
Alexandrov TL, Khalif IL, Khalif AY, Khismatullina ZR, Shapina MV. Skin diseases and inflammatory bowel diseases. Literature review. Meditsinskiy sovet = Medical Council. 2020;(5):114-119. (In Russ.) https://doi.org/10.21518/2079-701X-2020-5-114-119
Views:
929
Email this article 